Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

785 - Efficacy of Ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer.

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Yosuke Katata

Citation

Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431

Authors

Y. Katata1, T. Nagasaka1, H. Tanioka1, A. Nyuya1, T. Toshima2, Y. Mori2, K. Shigeyasu2, M. Okawaki1, M. Yamamura1, A. Tsuruta3, T. Ueno3, Y. Yamaguchi1

Author affiliations

  • 1 Medical Oncology, Kawasaki Medical School Hospital, 701-0192 - Kurashiki/JP
  • 2 Gastroenterological Surgery, Okayama University Hospital, 700-8558 - Okayama/JP
  • 3 Digestive Surgery, Kawasaki Medical School Hospital, 701-0192 - Kurashiki/JP
More

Resources

Abstract 785

Background

Ramucirumab is a human IgG-1 monoclonal antibody that targets the extracellular domain of VEGF receptor 2. We assessed the efficacy of ramucirumab in combination with second-line (2nd-line) or salvage-line (third- line or later) FOLFIRI (leucovorin, fluorouracil [5FU], and irinotecan) in patients with advanced metastatic colorectal cancer (CRC), retrospectively.

Methods

Patients who received ramucirumab with FOLFIRI in 2nd-line or salvage-line were enrolled. All patients were initially treated by ramucirumab (8mb/kg), irinotecan (150mg/m2), 5FU bolus (400mg/m2), l-LV (200mg/m2), and 5FU ci (2,400mg/m2). Efficacies were evaluated by progression free survival (PFS), overall survival (OS) after receiving ramucirumab regimens, over all response rate (ORR), and the resection rate of liver metastases (RRLM).

Results

We enrolled 33 patients. RAS mutations were observed in 22 patients (67%) and BRAF V600E mutation was fund in one cases (3%). Among them, 18 patients (55%) received ramucirumab with FOLFIRI in 2nd-line while 15 patients (45%) in salvage line. Median PFS was 5 months (95% CI: 3–10) for patients received ramucirumab in 2nd-line versus 2 months (95% CI: 1–3) for patients in salvage-line. Median overall survival after ramucirumab treatment was 19 months (95% CI: 11–not calculated) for patients received ramucirumab in 2nd-line versus 8 months (95% CI: 5–9) for patients in salvage-line. ORR was observed in 83% (15 patients) of 2nd-line and40% (6 patients) of salvage-line. Interestingly, the patients with BRAF V600E mutation was treated by Ramucirumab with FOLFIRI in salvage-line confirmed as stable disease. Of 18 patients received ramucirumab with FOLFIRI in 2nd-line, 10 patients (56%) had unresectable liver metastases before treatment. Of the 10 patients with liver metastases, 4 patients could be resected liver metastases after ramucirumab treatment (RRLM is 40%). Although, in salvage-line, nine of 15 patients (60%) had unresectable liver metastases before treatment, the nine patients could not have reached liver resection (RRLM is 0%).

Conclusions

Ramucirumab with FOLFIRI in 2nd-line treatment will be effective and tolerable for metastatic CRC patients with a higher liver resection rate.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Kawasaki Medical School.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.